Combination therapy with inhaled nitric oxide and intravenous dobutamine during pulmonary hypertension in the rabbit

Journal of Cardiovascular Pharmacology

Volumn 36, Issue 2, 2000, Pages 146-151

  Bradford, Katherine Kilroy ^a   Deb, Bhaskar ^a   Pearl, Ronald G ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dobutamine; Inhaled nitric oxide; Pulmonary hypertension; Right ventricular failure; Vasodilator

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; DOBUTAMINE; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; HEART OUTPUT; LUNG ARTERY PRESSURE; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VASODILATATION;

EID: 0033843609     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200036001-00093     Document Type: Article

References (51)

1. Primary pulmonary hypertension
2. Pulmonary hypertension: Newer concepts in diagnosis and management
3. The pressure-overloaded right ventricle in pulmonary hypertension
4. Therapeutic options for severe pulmonary hypertension
5. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
6. The pharmacology and physiology of nitric oxide: Understanding its use in anesthesia and critical care medicine
7. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure
8. The use of inhaled nitric oxide in a wide variety of clinical problems
9. Selective pulmonary and systemic vasodilator effects of amrinone in children: New therapeutic implications
10. Milrinone and postoperative pulmonary hypertension
11. Dobutamine: Ten years later
12. 2 mimetic-induced pulmonary hypertension in newborn lambs
13. Volume expansion, dobutamine and noradrenaline for treatment of right ventricular dysfunction in porcine septic shock: A combined invasive and radionuclide study
14. Vasodilatory effects of milrinone on pulmonary vasculature in dogs with pulmonary hypertension due to pulmonary embolism: A comparison with those of dopamine and dobutamine
15. Amrinone versus dobutamine in cardiac surgical patients with severe pulmonary hypertension after cardiopulmonary bypass: A prospective, randomized double-blinded trial
16. Cardiopulmonary effects of enoximone or dobutamine and nitroglycerin on mitral valve regurgitation and pulmonary venous hypertension
17. Amrinone versus dobutamine in cardiac surgical patients with severe pulmonary hypertension after cardiopulmonary bypass: A prospective, randomized double-blinded trial
18. Pharmacologic reduction pretransplantation pulmonary vascular resistance predicts outcome after pediatric heart transplantation
19. Effects of dobutamine and/or nitroprusside on the pulmonary circulation in patients with pulmonary hypertension secondary to end-stage heart failure
20. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: Role of phosphodiesterase 3
21. Synergistic action of vasodilators that increase cGMP and cAMP in the hamster cremaster microcirculation
22. Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle
23. Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension
24. Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia
25. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: A dose-response study and comparison with prostacyclin
26. Combination of inhaled nitric oxide with iv nitroglycerin or with a prostacyclin analogue in the treatment of experimental pulmonary hypertension
27. Combined therapy with inhaled nitric oxide and intravenous vasodilators during acute and chronic experimental pulmonary hypertension
28. Additive effects of inhaled prostacyclin and inhaled nitric oxide in reducing experimental pulmonary hypertension
29. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide
30. Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus
31. Effective control of refractory pulmonary hypertension after cardiac operations
32. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
33. 2 concentration in pulmonary hypertension associated with congenital heart disease
34. 2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease
35. Bacterial lipopolysaccharide induction of the prostaglandin G/H synthase 2 gene causes thromboxane-dependent pulmonary hypertension in rabbits
36. 2 and prostacyclin in the early pulmonary hypertension after porcine meconium aspiration
37. 2 excretion in pigs
38. Heparin-protamine complexes cause pulmonary hypertension in goats
39. Prevention of complement-induced pulmonary hypertension and improvement of right ventricular function by selective thromboxane receptor antagonism
40. Thromboxane contributes to pulmonary hypertension in ischemia-reperfusion lung injury
41. Inhibition of endogenous nitric oxide synthesis potentiates the effects of sodium nitroprusside but not of adenosine in experimental pulmonary hypertension
42. Inhaled nitric oxide potentiates actions of adenosine but not of sodium nitroprusside in experimental pulmonary hypertension
43. 1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension
44. Vasodilator therapy in vasoconstrictor-induced pulmonary hypertension in sheep
45. 1, isoproterenol, prostacyclin, and nifedipine in vasoconstrictor pulmonary hypertension in sheep
46. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension
47. 2 mimetic U-46619 induces systemic and pulmonary hypertension and delayed tachypnea in the goat
48. Inhaled nitric oxide, oxygen, and alkalosis: Dose-response interactions in a lamb model of pulmonary hypertension
49. Aerosolization of novel nitric oxide donors selectively reduce pulmonary hypertension
50. Efficacy of inhaled prostanoids in experimental pulmonary hypertension
51. Pulmonary vasodilation by nitric oxide gas and prodrug aerosols in acute pulmonary hypertension